317 related articles for article (PubMed ID: 33232124)
1. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy
Li Y; Zhao R; Cheng K; Zhang K; Wang Y; Zhang Y; Li Y; Liu G; Xu J; Xu J; Anderson GJ; Shi J; Ren L; Zhao X; Nie G
ACS Nano; 2020 Dec; 14(12):16698-16711. PubMed ID: 33232124
[TBL] [Abstract][Full Text] [Related]
2. Mass-produced gram-negative bacterial outer membrane vesicles activate cancer antigen-specific stem-like CD8
Won S; Lee C; Bae S; Lee J; Choi D; Kim MG; Song S; Lee J; Kim E; Shin H; Basukala A; Lee TR; Lee DS; Gho YS
J Extracell Vesicles; 2023 Aug; 12(8):e12357. PubMed ID: 37563797
[TBL] [Abstract][Full Text] [Related]
3. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
4. Bioengineered bacterial outer membrane vesicles encapsulated Polybia-mastoparan I fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory chemotherapy.
Ren C; Li Y; Cong Z; Li Z; Xie L; Wu S
Front Immunol; 2023; 14():1129771. PubMed ID: 36999028
[TBL] [Abstract][Full Text] [Related]
5. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.
Jin M; Huo D; Sun J; Hu J; Liu S; Zhan M; Zhang BZ; Huang JD
J Nanobiotechnology; 2024 Jan; 22(1):15. PubMed ID: 38166929
[TBL] [Abstract][Full Text] [Related]
6. Surface Mineralization of Engineered Bacterial Outer Membrane Vesicles to Enhance Tumor Photothermal/Immunotherapy.
Chen X; Li P; Luo B; Song C; Wu M; Yao Y; Wang D; Li X; Hu B; He S; Zhao Y; Wang C; Yang X; Hu J
ACS Nano; 2024 Jan; 18(2):1357-1370. PubMed ID: 38164903
[TBL] [Abstract][Full Text] [Related]
7. Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy.
Pan J; Li X; Shao B; Xu F; Huang X; Guo X; Zhou S
Adv Mater; 2022 Feb; 34(7):e2106307. PubMed ID: 34859919
[TBL] [Abstract][Full Text] [Related]
8. Bacterial outer membrane vesicles induce a transcriptional shift in arabidopsis towards immune system activation leading to suppression of pathogen growth in planta.
Chalupowicz L; Mordukhovich G; Assoline N; Katsir L; Sela N; Bahar O
J Extracell Vesicles; 2023 Jan; 12(1):e12285. PubMed ID: 36645092
[TBL] [Abstract][Full Text] [Related]
9. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor.
Su LY; Tian Y; Zheng Q; Cao Y; Yao M; Wang S; Xu W; Xi C; Clocchiatti A; Nie G; Zhou H
Cell Chem Biol; 2024 Jan; ():. PubMed ID: 38309277
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy.
Cui C; He Q; Wang J; Kang J; Ma W; Nian Y; Sun Z; Weng H
Int J Biol Macromol; 2023 Aug; 247():125692. PubMed ID: 37414322
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
15. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
16. Inflammasome Activation by Bacterial Outer Membrane Vesicles Requires Guanylate Binding Proteins.
Finethy R; Luoma S; Orench-Rivera N; Feeley EM; Haldar AK; Yamamoto M; Kanneganti TD; Kuehn MJ; Coers J
mBio; 2017 Oct; 8(5):. PubMed ID: 28974614
[TBL] [Abstract][Full Text] [Related]
17. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
18. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
[TBL] [Abstract][Full Text] [Related]
19. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
20. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
